Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
466 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 25.71 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 4.01 | Oscillator | Buy |
| Williams %R (14) | -97.81 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.56 (Hist -0.03) | Oscillator | Strong Sell |
| Average Directional Index (14) | 31.41 (+DI 12.7 / -DI 30.8) | Trend | Strong Sell |
Annual filings (FY) with consensus forward estimates (hatched)
| EMA 20 | 6.69 | MA | Strong Sell |
| SMA 20 | 6.77 | MA | Strong Sell |
| EMA 50 | 7.48 | MA | Strong Sell |
| SMA 50 | 7.89 | MA | Strong Sell |
| SMA 200 | 7.35 | MA | Strong Sell |
Current price $5.87
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 14, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Aug 14, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| May 15, 26 | Barclays | maintain | Overweight | Overweight |
| Mar 27, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
FY2025 · 10-K disclosure
Stock news · updated daily
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full German regulatory clearance for its pivotal PARADIGM trial, allowing the company to begin recruiting patients in Europe's largest transcatheter aortic valve replacement market. Germany's Federal Institute for Drugs and Medical Devices has cleared the DurAVR® Transcatheter Heart Valve study for patients with severe calcific aortic stenosis, opening the way for Anteris to activate leading German clinical centres and broaden the trial's European footprint.
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial's European footprint.
Anteris Technologies Global Corp. (NASDAQ: AVR - Get Free Report) major shareholder L1 Capital Pty Ltd bought 272,695 shares of the business's stock in a transaction on Tuesday, October 6th. The shares were purchased at an average cost of $7.18 per share, with a total value of $1,957,950.10. Following the transaction, the insider owned 6,358,271 shares
Anteris Technologies Global Corp. (NASDAQ: AVR - Get Free Report) major shareholder L1 Capital Pty Ltd acquired 648,455 shares of the firm's stock in a transaction on Monday, October 5th. The shares were acquired at an average price of $7.51 per share, with a total value of $4,869,897.05. Following the completion of the transaction, the insider
Anteris Technologies Global Corp. (NASDAQ: AVR - Get Free Report) major shareholder L1 Capital Pty Ltd bought 236,354 shares of the company's stock in a transaction on Friday, October 2nd. The shares were acquired at an average price of $7.78 per share, with a total value of $1,838,834.12. Following the transaction, the insider directly owned 12,129,925
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September...
BlackRock Inc. bought a new position in shares of Anteris Technologies Global Corp. (NASDAQ: AVR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,771,213 shares of the company's stock, valued at approximately $56,846,000. BlackRock Inc. owned approximately 5.93%
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The details of each conference are as follows: Cantor Global Healthcare Conference Date: Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Room: Track 1 – Metropolitan Room Location: Waldorf Astoria Hotel, New York Wells Fargo Healthcare Conference Date: Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST) Room: Track 1 – Picasso 6 Location: Encore Boston Harbor Hotel, Boston Morgan Stanley Healthcare Conference Date: Monday, September 14, 2026 (US time) Format: Fireside chat with Morgan Stanley Healthcare Team Time: 9:15AM (US EST) Room: Soho Complex 7th Floor Location: Sheraton Times Square Hotel, New York About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.21 | -0.30 | Miss -44.7% | $1.01M |
| May 12, 2026 | -0.27 | -0.28 | Miss -3.4% | $494.0K |
| Mar 11, 2026 | -0.50 | -0.74 | Miss -47.0% | $303.0K |
| Nov 10, 2025 | -0.54 | -0.62 | Miss -14.3% | $429.0K |
| Aug 12, 2025 | -0.55 | -0.58 | Miss -6.4% | $618.0K |
| May 13, 2025 | -0.49 | -0.61 | Miss -24.2% | $556.0K |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | L1 Capital Pty Ltd | 10 percent owner | P-Purchase | 272,695 @ $7.18 | $1.96M |
| Oct 5, 26 |
| L1 Capital Pty Ltd |
| 10 percent owner |
| P-Purchase |
| 648,455 @ $7.51 |
| $4.87M |
| Oct 2, 26 | L1 Capital Pty Ltd | 10 percent owner | P-Purchase | 236,354 @ $7.78 | $1.84M |
| Oct 1, 26 | L1 Capital Pty Ltd | 10 percent owner | P-Purchase | 322,940 @ $7.60 | $2.45M |
| Sep 30, 26 | L1 Capital Pty Ltd | 10 percent owner | P-Purchase | 74,286 @ $7.72 | $573.5K |
| Sep 11, 26 | Moen Brent | officer: Chief Financial Officer | A-Award | 90,274 @ $8.35 | $753.8K |
| Sep 11, 26 | Moen Brent | 0 | — |
| Aug 28, 26 | L1 Capital Pty Ltd | 10 percent owner | S-Sale | 7,800 @ $8.83 | $68.87K |
| 8-K | Sep 23, 2026 | 2026-09-23 07:30:21 | View |
| 424B3 | Sep 21, 2026 | 2026-09-21 09:15:34 | View |
| 8-K | Sep 17, 2026 | 2026-09-17 17:00:34 | View |
| 4 | Sep 16, 2026 | 2026-09-16 14:18:20 | View |
| 3 | Sep 16, 2026 | 2026-09-16 14:16:54 | View |
| 424B3 | Sep 9, 2026 | 2026-09-09 16:15:22 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | AVR | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.1x | -5.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -4.9x | EPS est. -1.21 | Elevated |
| Price / Book | 2.3x | -385.4x | Discount |
| Price / Sales | 255.2x | 61.8x | Elevated |
| EV / EBITDA | -3.2x | -5.1x | Discount |
| Return on equity | -77.7% | — | Weak |
| Gross margin | 37.0% | 20.9% | Above hist. |
| Debt / Equity | 0.01 | -4.79 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 14.14 | Safe zone |
Discounted cash flow model